1,2,3,4-tetrahydroisoquinoline has been researched along with Hyperglycemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukui, M; Hirono, S; Ito, Y; Kitao, T; Miike, T; Morishita, K; Ozawa, SI; Shirahase, H; Takeda, S | 1 |
| Bai, G; Huan, Y; Jia, C; Li, C; Li, R; Liu, Q; Liu, S; Liu, Z; Pan, X; Peng, J; Shen, Z; Sun, S; Wang, X; Zhou, T | 1 |
2 other study(ies) available for 1,2,3,4-tetrahydroisoquinoline and Hyperglycemia
| Article | Year |
|---|---|
(S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.
Topics: Administration, Oral; Animals; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Experimental; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Transgenic; Molecular Docking Simulation; Molecular Structure; PPAR gamma; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines | 2019 |
A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice.
Topics: 3T3-L1 Cells; Adipogenesis; Animals; Body Weight; Dyslipidemias; Fatty Liver; HEK293 Cells; Humans; Hyperglycemia; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; PPAR gamma; Tetrahydroisoquinolines | 2019 |